Global /Australia /Healthcare /Biotechnology /1AD

AdAlta Ltd.

1AD

• ASX: 1AD • Delayed

0.0050AUD 0%

0.0035 USD

As of 14 June 2026, AdAlta Ltd. has a market cap of $8.96M USD, ranking #41860 globally and #1356 in Australia. It ranks #3705 in the Healthcare sector, and #726 in the Biotechnology industry.

Global Rank

41860

Country Rank

1356

Sector Rank

3705

Industry Rank

726

Key Stats

Market Cap

$8.96MUSD

12.75M AUD

Enterprise Value

$7.87MUSD

11.16M AUD

Revenue (TTM)

$427.42KUSD

608.07K AUD

EBITDA (TTM)

-$2.93MUSD

-4.16M AUD

Net Income (TTM)

-$3.07MUSD

-4.36M AUD

PS Ratio

21.0

PB Ratio

-58.3

Company Profile

Country (HQ)

Australia

Sector

Healthcare

Industry

Biotechnology

CEO

Timothy Oldham open_in_new

Employees

Founded

2006

Website

adalta.com.au open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	25%	25%	-25%	43%	67%	50%	-80%	-97%

News

Markets

Exchange	Ticker	Price	Quotes
Australian Securities Exchange (ASX) MIC: XASX PRIMARY	1AD AdAlta Ltd ISIN: AU0000001AD2 Shares Out.: Shares Outstanding: 2.656B¹ Shares Float: 2.035B² TV: TradingView: ASX: 1AD SA: Stock Analysis: ASX: 1AD YF: Yahoo Finance: 1AD.AX GF: Google Finance: ASX: 1AD BA: Barron's: 1AD MS: Morningstar: XASX: 1AD	0.0050 AUD	TV: TradingView: ASX: 1AD SA: Stock Analysis: ASX: 1AD YF: Yahoo Finance: 1AD.AX GF: Google Finance: ASX: 1AD BA: Barron's: 1AD MS: Morningstar: XASX: 1AD

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About AdAlta Ltd.

AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration. It has discovered WD-34 for the multiple malaria species, Babesia, and Toxoplasma in collaboration with La Trobe University. The company was incorporated in 2006 and is based in Camberwell, Australia.

Similar Companies

Industry: Biotechnology (Australia)

Name	Market Cap (USD) diff.	PE	Country
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 473K%	29.3	Australia
Telix Pharmaceuticals Ltd. ASX: TLX	$3.58B 5.09B AUD 40K%	-	Australia
Mesoblast Ltd. ASX: MSB	$2.02B 2.88B AUD 22K%	-	Australia
PolyNovo Ltd. ASX: PNV	$490.46M 697.75M AUD 5K%	71.8	Australia
Kazia Therapeutics Ltd. NASDAQ: KZIA	$141.64M 1K%	-	Australia
Immutep Ltd. ASX: IMM	$65.26M 92.84M AUD 628%	-	Australia

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 2M%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 2M%	19.0	United States
argenx SE EBR: ARGX	$47.84B 41.39B EUR 534K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 500K%	35.5	South Korea
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 472K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 314K%	43.8	South Korea

chevron_leftBack